Cargando…

Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells

Poly (ADP-ribose) polymerase inhibitor (PARPi) resistance is a new challenge for antitumor therapy. The purpose of this study was to investigate the reversal effects of chidamide on fluzoparib resistance, a PARPi, and its mechanism of action. A fluzoparib-resistant triple-negative breast cancer (TNB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xinyang, Yuan, Xiang, Wang, Ziming, Li, Jing, Liu, Zhiwei, Wang, Yukun, Wei, Limin, Li, Yuanpei, Wang, Xinshuai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894594/ https://www.ncbi.nlm.nih.gov/pubmed/35251986 http://dx.doi.org/10.3389/fonc.2022.819714

Ejemplares similares

The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
por: Wang, Yukun, et al.
Publicado: (2021)

The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer
por: Li, Jing, et al.
Publicado: (2023)

MiR-16-5p suppresses breast cancer proliferation by targeting ANLN
por: Wang, Ziming, et al.
Publicado: (2021)

Bioinformatics analysis on enrichment analysis of potential hub genes in breast cancer
por: Wei, Limin, et al.
Publicado: (2021)

The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
por: Wang, Chaokun, et al.
Publicado: (2021)

Apatinib enhances the anti-tumor effect of paclitaxel via the PI3K/p65/Bcl-xl pathway in triple-negative breast cancer
por: Chen, Jing, et al.
Publicado: (2021)

Chidamide Combined With Doxorubicin Induced p53-Driven Cell Cycle Arrest and Cell Apoptosis Reverse Multidrug Resistance of Breast Cancer
por: Cao, Lixia, et al.
Publicado: (2021)

A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials
por: Wang, Yukun, et al.
Publicado: (2020)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

The Combination of Icotinib Hydrochloride and Fluzoparib Enhances the Radiosensitivity of Biliary Tract Cancer Cells
por: Zhu, Linggang, et al.
Publicado: (2020)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Pharmacologic characterization of fluzoparib, a novel poly(ADP‐ribose) polymerase inhibitor undergoing clinical trials
por: Wang, Lei, et al.
Publicado: (2019)

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

LCOR Reverses Immune-Checkpoint Inhibitors Therapy Resistance Out of IFN Constraint in Triple-Negative Breast Cancer
por: Zhou, Jialin, et al.
Publicado: (2022)

Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review
por: Yan, Zheng, et al.
Publicado: (2020)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

Modified conditioning regimen with chidamide and high‐dose rituximab for triple‐hit lymphoma
por: Kang, Junnan, et al.
Publicado: (2021)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

Analysis of CK5/6 and EGFR and Its Effect on Prognosis of Triple Negative Breast Cancer
por: Wang, Zhen, et al.
Publicado: (2021)

Rewiring of the Endocrine Network in Triple-Negative Breast Cancer
por: Li, Kaixuan, et al.
Publicado: (2022)

ASMT Regulates Tumor Metastasis Through the Circadian Clock System in Triple-Negative Breast Cancer
por: Xie, FenFen, et al.
Publicado: (2020)

Construction and Identification of New Molecular Markers of Triple-Negative Breast Cancer Stem Cells
por: Liu, Tingting, et al.
Publicado: (2021)

Construction and Validation of Nomograms Predicting Survival in Triple-Negative Breast Cancer Patients of Childbearing Age
por: Cui, Xiang, et al.
Publicado: (2021)

SIPL1, Regulated by MAZ, Promotes Tumor Progression and Predicts Poor Survival in Human Triple-Negative Breast Cancer
por: He, Juanjuan, et al.
Publicado: (2021)

Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib
por: Song, Xiang, et al.
Publicado: (2020)

LncRNA ENST869 Targeting Nestin Transcriptional Region to Affect the Pharmacological Effects of Chidamide in Breast Cancer Cells
por: Feng, Xiuyan, et al.
Publicado: (2022)

Nomogram for Predicting Lymph Node Involvement in Triple-Negative Breast Cancer
por: Cui, Xiang, et al.
Publicado: (2020)

Ferroptosis and triple-negative breast cancer: Potential therapeutic targets
por: Xu, Na, et al.
Publicado: (2022)

Characteristics of recurrence, predictors for relapse and prognosis of rapid relapse triple-negative breast cancer
por: Cai, Shuang-Long, et al.
Publicado: (2023)

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
por: Liu, Weiping, et al.
Publicado: (2021)

Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
por: Li, Huiping, et al.
Publicado: (2020)

Nanomaterial Technology and Triple Negative Breast Cancer
por: Hou, Kai, et al.
Publicado: (2022)

Identification of a novel glycolysis-related prognosis risk signature in triple-negative breast cancer
por: Ruan, Yuxia, et al.
Publicado: (2023)

Tumor-Associated Macrophages: Key Players in Triple-Negative Breast Cancer
por: Qiu, Xia, et al.
Publicado: (2022)

Correlation between the Warburg effect and progression of triple-negative breast cancer
por: Liu, Shaojun, et al.
Publicado: (2023)

Anti-triple-negative breast cancer metastasis efficacy and molecular mechanism of the STING agonist for innate immune pathway
por: Lu, Xing, et al.
Publicado: (2023)

High Expression of microRNA-223 Indicates a Good Prognosis in Triple-Negative Breast Cancer
por: Chen, Li, et al.
Publicado: (2021)

Chidamide Maintenance Therapy Following Induction Therapy in Patients With Peripheral T-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Case Series From China
por: Guo, Wei, et al.
Publicado: (2022)

Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer
por: Ding, Ran, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j4p3hrdktgg0g26bet3eujqd4k